Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$3.87 USD
+0.27 (7.50%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $3.88 +0.01 (0.26%) 7:58 PM ET
1-Strong Buy of 5 1
C Value C Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FULC 3.87 +0.27(7.50%)
Will FULC be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for FULC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FULC
STTK Discontinues Cancer Program, Plans Workforce Cut, Stock Falls
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag
FULC: What are Zacks experts saying now?
Zacks Private Portfolio Services
PRME Stock Rises 11.8% on Collaboration With Bristol Myers
AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
MRNA Begins Dosing in Pivotal Study on Norovirus Vaccine
Other News for FULC
Leerink sees little impact to genetic medicines from Pfizer's Oxbryta withdrawal
Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher
Fulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setback
Fulcrum reduces its workforce
Largest borrow rate increases among liquid names